Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Human Immunodeficiency Virus | Research article

Prepared for PrEP: preferences for HIV pre-exposure prophylaxis among Chinese men who have sex with men in an online national survey

Authors: Wenting Huang, Dan Wu, Jason J. Ong, M. Kumi Smith, Fan Yang, Hongyun Fu, Weiming Tang, Joseph D. Tucker

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

Pre-exposure prophylaxis (PrEP) is not widely available in China. Previous studies reported low awareness and inconclusive findings on the acceptability of PrEP among Chinese men who have sex with men (MSM).

Methods

We conducted a secondary analysis of an online national survey comparing preferences for oral and long-acting injectable PrEP among MSM and identifying correlates of preferences. The study did not collect detailed information about partner types that may influence negotiated safety and PrEP uptake.

Results

Nine-hundred and seventy-nine men from the larger sample of 1045 men responded to the PrEP survey questions. Most men (81.9%) had never heard of PrEP, but reported interest in using PrEP. More participants chose injectable PrEP (36.3%) as their preferred formulation than oral PrEP (24.6%). Men who had at least two HIV tests (adjusted OR = 1.36, 95%CI 1.04, 1.78) more commonly preferred injectable PrEP.

Conclusion

Our findings may help inform PrEP messaging in areas where PrEP has yet to be scaled up.
Appendix
Available only for authorised users
Literature
2.
go back to reference McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRef McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRef
3.
go back to reference Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRef Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRef
4.
go back to reference Dehne KL, Dallabetta G, Wilson D, Garnett GP, Laga M, Benomar E, Fakoya A, Baggaley RC, Nelson LJ, Kasedde S, et al. HIV prevention 2020: a framework for delivery and a call for action. Lancet HIV. 2016;3(7):e323–32.CrossRef Dehne KL, Dallabetta G, Wilson D, Garnett GP, Laga M, Benomar E, Fakoya A, Baggaley RC, Nelson LJ, Kasedde S, et al. HIV prevention 2020: a framework for delivery and a call for action. Lancet HIV. 2016;3(7):e323–32.CrossRef
5.
go back to reference Zhang L, Peng P, Wu Y, Ma X, Soe NN, Huang X, Wu H, Markowitz M, Meyers K. Modelling the epidemiological impact and cost-effectiveness of PrEP for HIV transmission in MSM in China. AIDS Behav. 2018;23:523–33.CrossRef Zhang L, Peng P, Wu Y, Ma X, Soe NN, Huang X, Wu H, Markowitz M, Meyers K. Modelling the epidemiological impact and cost-effectiveness of PrEP for HIV transmission in MSM in China. AIDS Behav. 2018;23:523–33.CrossRef
6.
go back to reference Mao X, Yu H, Hu QH, Zhang J, Chu ZX, Wang YN, Geng WQ, Jiang YJ, Xu JJ. Acceptability of pre-exposure HIV prophylaxis clinical trial among MSM in Shenyang city. Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38(8):1083–7.PubMed Mao X, Yu H, Hu QH, Zhang J, Chu ZX, Wang YN, Geng WQ, Jiang YJ, Xu JJ. Acceptability of pre-exposure HIV prophylaxis clinical trial among MSM in Shenyang city. Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38(8):1083–7.PubMed
7.
go back to reference Xue H, Liu H, Cai L. Analysis of willingness and influencing factors for usage of pre-exposure prophylaxis among men who have sex with men. Zhonghua Yu Fang Yi Xue Za Zhi. 2015;49(11):973–7.PubMed Xue H, Liu H, Cai L. Analysis of willingness and influencing factors for usage of pre-exposure prophylaxis among men who have sex with men. Zhonghua Yu Fang Yi Xue Za Zhi. 2015;49(11):973–7.PubMed
8.
go back to reference Zhou F, Gao L, Li S, Li D, Zhang L, Fan W, Yang X, Yu M, Xiao D, Yan L, et al. Willingness to accept HIV pre-exposure prophylaxis among Chinese men who have sex with men. PLoS One. 2012;7(3):e32329.CrossRef Zhou F, Gao L, Li S, Li D, Zhang L, Fan W, Yang X, Yu M, Xiao D, Yan L, et al. Willingness to accept HIV pre-exposure prophylaxis among Chinese men who have sex with men. PLoS One. 2012;7(3):e32329.CrossRef
9.
go back to reference Liu C, Ding Y, Ning Z, Gao M, Liu X, Wong FY, He N. Factors influencing uptake of pre-exposure prophylaxis: some qualitative insights from an intervention study of men who have sex with men in China. Sex Health. 2018;15(1):39–45.CrossRef Liu C, Ding Y, Ning Z, Gao M, Liu X, Wong FY, He N. Factors influencing uptake of pre-exposure prophylaxis: some qualitative insights from an intervention study of men who have sex with men in China. Sex Health. 2018;15(1):39–45.CrossRef
10.
go back to reference Qu D, Zhong X, Xiao G, Dai J, Liang H, Huang A. Adherence to pre-exposure prophylaxis among men who have sex with men: a prospective cohort study. Int J Infect Dis. 2018;75:52–9.CrossRef Qu D, Zhong X, Xiao G, Dai J, Liang H, Huang A. Adherence to pre-exposure prophylaxis among men who have sex with men: a prospective cohort study. Int J Infect Dis. 2018;75:52–9.CrossRef
11.
go back to reference Jackson T, Huang A, Chen H, Gao X, Zhong X, Zhang Y. Cognitive, psychosocial, and sociodemographic predictors of willingness to use HIV pre-exposure prophylaxis among Chinese men who have sex with men. AIDS Behav. 2012;16(7):1853–61.CrossRef Jackson T, Huang A, Chen H, Gao X, Zhong X, Zhang Y. Cognitive, psychosocial, and sociodemographic predictors of willingness to use HIV pre-exposure prophylaxis among Chinese men who have sex with men. AIDS Behav. 2012;16(7):1853–61.CrossRef
12.
go back to reference Zhang Y, Peng B, She Y, Liang H, Peng HB, Qian HZ, Vermund SH, Zhong XN, Huang A. Attitudes toward HIV pre-exposure prophylaxis among men who have sex with men in western China. AIDS Patient Care STDs. 2013;27(3):137–41.CrossRef Zhang Y, Peng B, She Y, Liang H, Peng HB, Qian HZ, Vermund SH, Zhong XN, Huang A. Attitudes toward HIV pre-exposure prophylaxis among men who have sex with men in western China. AIDS Patient Care STDs. 2013;27(3):137–41.CrossRef
13.
go back to reference Wei C, Raymond HF. Pre-exposure prophylaxis for men who have sex with men in China: challenges for routine implementation. J Int AIDS Soc. 2018;21(7):e25166.CrossRef Wei C, Raymond HF. Pre-exposure prophylaxis for men who have sex with men in China: challenges for routine implementation. J Int AIDS Soc. 2018;21(7):e25166.CrossRef
14.
go back to reference Tatham LM, Savage AC, Dwyer A, Siccardi M, Scott T, Vourvahis M, Clark A, Rannard SP, Owen A. Towards a Maraviroc long-acting injectable nanoformulation. Eur J Pharm Biopharm. 2019;138:92–8.CrossRef Tatham LM, Savage AC, Dwyer A, Siccardi M, Scott T, Vourvahis M, Clark A, Rannard SP, Owen A. Towards a Maraviroc long-acting injectable nanoformulation. Eur J Pharm Biopharm. 2019;138:92–8.CrossRef
15.
go back to reference Schlesinger E, Johengen D, Luecke E, Rothrock G, McGowan I, van der Straten A, Desai T. A tunable, biodegradable, thin-film polymer device as a long-acting implant delivering Tenofovir Alafenamide Fumarate for HIV pre-exposure prophylaxis. Pharm Res. 2016;33(7):1649–56.CrossRef Schlesinger E, Johengen D, Luecke E, Rothrock G, McGowan I, van der Straten A, Desai T. A tunable, biodegradable, thin-film polymer device as a long-acting implant delivering Tenofovir Alafenamide Fumarate for HIV pre-exposure prophylaxis. Pharm Res. 2016;33(7):1649–56.CrossRef
16.
go back to reference Meyers K, Wu Y, Qian H, Sandfort T, Huang X, Xu J, Zhang J, Xia W, Glidden D, Wu H, et al. Interest in long-acting injectable PrEP in a cohort of men who have sex with men in China. AIDS Behav. 2018;22(4):1217–27.CrossRef Meyers K, Wu Y, Qian H, Sandfort T, Huang X, Xu J, Zhang J, Xia W, Glidden D, Wu H, et al. Interest in long-acting injectable PrEP in a cohort of men who have sex with men in China. AIDS Behav. 2018;22(4):1217–27.CrossRef
17.
go back to reference Parsons JT, Rendina HJ, Whitfield TH, Grov C. Familiarity with and preferences for Oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a National Sample of gay and bisexual men in the U.S. AIDS Behav. 2016;20(7):1390–9.CrossRef Parsons JT, Rendina HJ, Whitfield TH, Grov C. Familiarity with and preferences for Oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a National Sample of gay and bisexual men in the U.S. AIDS Behav. 2016;20(7):1390–9.CrossRef
18.
go back to reference Ding Y, Yan H, Ning Z, Cai X, Yang Y, Pan R, Zhou Y, Zheng H, Gao M, Rou K, et al. Low willingness and actual uptake of pre-exposure prophylaxis for HIV-1 prevention among men who have sex with men in Shanghai, China. Biosci Trends. 2016;10(2):113–9.CrossRef Ding Y, Yan H, Ning Z, Cai X, Yang Y, Pan R, Zhou Y, Zheng H, Gao M, Rou K, et al. Low willingness and actual uptake of pre-exposure prophylaxis for HIV-1 prevention among men who have sex with men in Shanghai, China. Biosci Trends. 2016;10(2):113–9.CrossRef
19.
go back to reference Wang Z, Lau JTF, Fang Y, Ip M, Gross DL. Prevalence of actual uptake and willingness to use pre-exposure prophylaxis to prevent HIV acquisition among men who have sex with men in Hong Kong, China. PLoS One. 2018;13(2):e0191671.CrossRef Wang Z, Lau JTF, Fang Y, Ip M, Gross DL. Prevalence of actual uptake and willingness to use pre-exposure prophylaxis to prevent HIV acquisition among men who have sex with men in Hong Kong, China. PLoS One. 2018;13(2):e0191671.CrossRef
20.
go back to reference Shan J. Gay men find HIV drug in Thailand, not China. Beijing: China Daily; 2017. Shan J. Gay men find HIV drug in Thailand, not China. Beijing: China Daily; 2017.
21.
go back to reference Pan SW, Durvasula M, Ong JJ, Liu C, Tang W, Fu H, Wei C, Wang C, Terris-Prestholt F, Tucker JD. No place like home? Disentangling Preferences for HIV Testing Locations and Services Among Men Who Have Sex with Men in China. AIDS Behav. 2018;23:847–859.CrossRef Pan SW, Durvasula M, Ong JJ, Liu C, Tang W, Fu H, Wei C, Wang C, Terris-Prestholt F, Tucker JD. No place like home? Disentangling Preferences for HIV Testing Locations and Services Among Men Who Have Sex with Men in China. AIDS Behav. 2018;23:847–859.CrossRef
22.
go back to reference Zhang TP, Liu C, Han L, Tang W, Mao J, Wong T, Zhang Y, Tang S, Yang B, Wei C. Community engagement in sexual health and uptake of HIV testing and syphilis testing among MSM in China: a cross-sectional online survey. J Int AIDS Soc. 2017;20(1):21372.CrossRef Zhang TP, Liu C, Han L, Tang W, Mao J, Wong T, Zhang Y, Tang S, Yang B, Wei C. Community engagement in sexual health and uptake of HIV testing and syphilis testing among MSM in China: a cross-sectional online survey. J Int AIDS Soc. 2017;20(1):21372.CrossRef
23.
go back to reference Oldenburg CE, Le B, Huyen HT, Thien DD, Quan NH, Biello KB, Nunn A, Chan PA, Mayer KH, Mimiaga MJ, et al. Antiretroviral pre-exposure prophylaxis preferences among men who have sex with men in Vietnam: results from a nationwide cross-sectional survey. Sex Health. 2016;13:465–473.CrossRef Oldenburg CE, Le B, Huyen HT, Thien DD, Quan NH, Biello KB, Nunn A, Chan PA, Mayer KH, Mimiaga MJ, et al. Antiretroviral pre-exposure prophylaxis preferences among men who have sex with men in Vietnam: results from a nationwide cross-sectional survey. Sex Health. 2016;13:465–473.CrossRef
24.
go back to reference Mosley T, Khaketla M, Armstrong HL, Cui Z, Sereda P, Lachowsky NJ, Hull MW, Olarewaju G, Jollimore J, Edward J, et al. Trends in awareness and use of HIV PrEP among gay, bisexual, and other men who have sex with men in Vancouver, Canada 2012-2016. AIDS Behav. 2018;22(11):3550–65.CrossRef Mosley T, Khaketla M, Armstrong HL, Cui Z, Sereda P, Lachowsky NJ, Hull MW, Olarewaju G, Jollimore J, Edward J, et al. Trends in awareness and use of HIV PrEP among gay, bisexual, and other men who have sex with men in Vancouver, Canada 2012-2016. AIDS Behav. 2018;22(11):3550–65.CrossRef
25.
go back to reference Strauss BB, Greene GJ, Phillips G 2nd, Bhatia R, Madkins K, Parsons JT, Mustanski B. Exploring patterns of awareness and use of HIV pre-exposure prophylaxis among young men who have sex with men. AIDS Behav. 2017;21(5):1288–98.CrossRef Strauss BB, Greene GJ, Phillips G 2nd, Bhatia R, Madkins K, Parsons JT, Mustanski B. Exploring patterns of awareness and use of HIV pre-exposure prophylaxis among young men who have sex with men. AIDS Behav. 2017;21(5):1288–98.CrossRef
26.
go back to reference Hoagland B, De Boni RB, Moreira RI, Madruga JV, Kallas EG, Goulart SP, Cerqueira N, Torres TS, Luz PM, Fernandes NM, et al. Awareness and willingness to use pre-exposure prophylaxis (PrEP) among men who have sex with men and transgender women in Brazil. AIDS Behav. 2017;21(5):1278–87.CrossRef Hoagland B, De Boni RB, Moreira RI, Madruga JV, Kallas EG, Goulart SP, Cerqueira N, Torres TS, Luz PM, Fernandes NM, et al. Awareness and willingness to use pre-exposure prophylaxis (PrEP) among men who have sex with men and transgender women in Brazil. AIDS Behav. 2017;21(5):1278–87.CrossRef
27.
go back to reference Biello KB, Edeza A, Montgomery MC, Almonte A, Chan PA. Risk Perception and Interest in HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men with Rectal Gonorrhea and Chlamydia Infection. Arch Sex Behav. 2018;28:1185–1190.CrossRef Biello KB, Edeza A, Montgomery MC, Almonte A, Chan PA. Risk Perception and Interest in HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men with Rectal Gonorrhea and Chlamydia Infection. Arch Sex Behav. 2018;28:1185–1190.CrossRef
29.
go back to reference Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.CrossRef Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.CrossRef
30.
go back to reference Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS One. 2014;9(12):e114700.CrossRef Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS One. 2014;9(12):e114700.CrossRef
31.
go back to reference Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, Kanungi J, Singh S, Haberer J, Priddy F, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162–72.CrossRef Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, Kanungi J, Singh S, Haberer J, Priddy F, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162–72.CrossRef
32.
go back to reference Fisher CB, Fried AL, Ibrahim Puri L, Macapagal K, Mustanski B. “Free testing and PrEP without outing myself to parents:” motivation to participate in oral and injectable PrEP clinical trials among adolescent men who have sex with men. PLoS One. 2018;13(7):e0200560.CrossRef Fisher CB, Fried AL, Ibrahim Puri L, Macapagal K, Mustanski B. “Free testing and PrEP without outing myself to parents:” motivation to participate in oral and injectable PrEP clinical trials among adolescent men who have sex with men. PLoS One. 2018;13(7):e0200560.CrossRef
33.
go back to reference Cahill S, Taylor SW, Elsesser SA, Mena L, Hickson D, Mayer KH. Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care. 2017;29(11):1351–8.CrossRef Cahill S, Taylor SW, Elsesser SA, Mena L, Hickson D, Mayer KH. Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care. 2017;29(11):1351–8.CrossRef
34.
go back to reference Liu Y, Osborn CY, Qian HZ, Yin L, Xiao D, Ruan Y, Simoni JM, Zhang X, Shao Y, Vermund SH, et al. Barriers and facilitators of linkage to and engagement in HIV care among HIV-positive men who have sex with men in China: a qualitative study. AIDS Patient Care STDs. 2016;30(2):70–7.CrossRef Liu Y, Osborn CY, Qian HZ, Yin L, Xiao D, Ruan Y, Simoni JM, Zhang X, Shao Y, Vermund SH, et al. Barriers and facilitators of linkage to and engagement in HIV care among HIV-positive men who have sex with men in China: a qualitative study. AIDS Patient Care STDs. 2016;30(2):70–7.CrossRef
Metadata
Title
Prepared for PrEP: preferences for HIV pre-exposure prophylaxis among Chinese men who have sex with men in an online national survey
Authors
Wenting Huang
Dan Wu
Jason J. Ong
M. Kumi Smith
Fan Yang
Hongyun Fu
Weiming Tang
Joseph D. Tucker
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4692-x

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.